Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction (NCT06483750) | Clinical Trial Compass
CompletedNot Applicable
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
United States30 participantsStarted 2024-06-03
Plain-language summary
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age greater than 18 at the time of informed consent
* Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions
* Upcoming scheduled senile cataract surgery
Exclusion Criteria:
* Eyelid abnormalities
* Patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
* Ocular surgery within the last 6 months
* Occlusion therapy with lacrimal or punctum plugs within the last 3 months
* Patients with an ocular surface abnormality that may compromise corneal integrity
* Patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months)
* Patients with cicatricial lid margin disease
* patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia
* Patients with permanent makeup or tattoos on their eyelids.
* Previous application/administration of Systane iLux or LipiFlow treatment
What they're measuring
1
Changed in Lipid Layer Thickness (LLT) measurement from baseline visit